These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30529752)

  • 1. Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas.
    Leijon H; Remes S; Hagström J; Louhimo J; Mäenpää H; Schalin-Jäntti C; Miettinen M; Haglund C; Arola J
    Hum Pathol; 2019 Apr; 86():66-75. PubMed ID: 30529752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas.
    Elston MS; Meyer-Rochow GY; Conaglen HM; Clarkson A; Clifton-Bligh RJ; Conaglen JV; Gill AJ
    Hum Pathol; 2015 Mar; 46(3):390-6. PubMed ID: 25554089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
    Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Warburg effect's manifestation in aggressive pheochromocytomas and paragangliomas: insights from a mouse cell model applied to human tumor tissue.
    Fliedner SM; Kaludercic N; Jiang XS; Hansikova H; Hajkova Z; Sladkova J; Limpuangthip A; Backlund PS; Wesley R; Martiniova L; Jochmanova I; Lendvai NK; Breza J; Yergey AL; Paolocci N; Tischler AS; Zeman J; Porter FD; Lehnert H; Pacak K
    PLoS One; 2012; 7(7):e40949. PubMed ID: 22859959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World.
    Patel M; Tena I; Jha A; Taieb D; Pacak K
    Front Endocrinol (Lausanne); 2021; 12():625312. PubMed ID: 33854479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin receptor subtype 2A expression and genetics in 184 paragangliomas: a single center retrospective observational study.
    Shen Y; Luo Y; Li M; Luo R; Chen L; Gao X; Jiang J; Liu Y; Lu Z; Zhang J
    Endocrine; 2024 Jul; 85(1):398-406. PubMed ID: 38306009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
    Turkova H; Prodanov T; Maly M; Martucci V; Adams K; Widimsky J; Chen CC; Ling A; Kebebew E; Stratakis CA; Fojo T; Pacak K
    Endocr Pract; 2016 Mar; 22(3):302-14. PubMed ID: 26523625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-Glycomic Profiling of Pheochromocytomas and Paragangliomas Separates Metastatic and Nonmetastatic Disease.
    Leijon H; Kaprio T; Heiskanen A; Satomaa T; Hiltunen JO; Miettinen MM; Arola J; Haglund C
    J Clin Endocrinol Metab; 2017 Nov; 102(11):3990-4000. PubMed ID: 28938401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma.
    Rao JU; Engelke UF; Rodenburg RJ; Wevers RA; Pacak K; Eisenhofer G; Qin N; Kusters B; Goudswaard AG; Lenders JW; Hermus AR; Mensenkamp AR; Kunst HP; Sweep FC; Timmers HJ
    Clin Cancer Res; 2013 Jul; 19(14):3787-95. PubMed ID: 23723300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of somatostatin receptors, dopamine D₂ receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas.
    Saveanu A; Muresan M; De Micco C; Taieb D; Germanetti AL; Sebag F; Henry JF; Brunaud L; Enjalbert A; Weryha G; Barlier A
    Endocr Relat Cancer; 2011 Apr; 18(2):287-300. PubMed ID: 21335363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors.
    Sadow PM; Rumilla KM; Erickson LA; Lloyd RV
    Endocr Pathol; 2008; 19(2):97-103. PubMed ID: 18461287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.
    Kubota A; Yamada Y; Kagimoto S; Shimatsu A; Imamura M; Tsuda K; Imura H; Seino S; Seino Y
    J Clin Invest; 1994 Mar; 93(3):1321-5. PubMed ID: 8132773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis.
    Kumar U; Sasi R; Suresh S; Patel A; Thangaraju M; Metrakos P; Patel SC; Patel YC
    Diabetes; 1999 Jan; 48(1):77-85. PubMed ID: 9892225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy.
    Pacak K; Kidd M; Meuter L; Modlin IM
    Endocr Relat Cancer; 2021 Oct; 28(11):731-744. PubMed ID: 34515661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
    Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
    Rischke HC; Benz MR; Wild D; Mix M; Dumont RA; Campbell D; Seufert J; Wiech T; Rössler J; Weber WA; Neumann HP
    J Nucl Med; 2012 Sep; 53(9):1352-8. PubMed ID: 22836345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Somatostatin receptors expression (SSTR1-SSTR5) in pheochromocytomas].
    Hubalewska-Dydejczyk A; Trofimiuk M; Sowa-Staszczak A; Gilis-Januszewska A; Wierzchowski W; Pach D; Budzyński A; Karcz D
    Przegl Lek; 2008; 65(9):405-7. PubMed ID: 19140390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pheochromocytoma/Paraganglioma: A Poster Child for Cancer Metabolism.
    Tevosian SG; Ghayee HK
    J Clin Endocrinol Metab; 2018 May; 103(5):1779-1789. PubMed ID: 29409060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
    Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases.
    Archier A; Varoquaux A; Garrigue P; Montava M; Guerin C; Gabriel S; Beschmout E; Morange I; Fakhry N; Castinetti F; Sebag F; Barlier A; Loundou A; Guillet B; Pacak K; Taïeb D
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1248-57. PubMed ID: 26637204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.